ugli look buyer weak
follow miss growth stori still solid
close report financi result miss street
consensu forecast wide margin test volum miss
estim revenu short forecast
result ugli probabl unexpect
secular growth stori record highest growth rate diagnost space
season typic focu investor gap access
bill test prior year weand streetsimpli miss
base expect asp rebound comfort manag
meet revenu guidanc maintain outperform
revis outlook incorpor higher spend investor attent
seem focus asp miss revers
season fundament chang manag guidanc
burn level guidanc direct line
manag comment follow financ ep goe
season hide plain sight use crude metric test access
divid report revenu came line
year gap access bill
test revers due high secular growth trend street
invest menu drive sustain growth expect aggress
invest technology-driven cost reduct menu expans
potenti direct-to-consum promot drive market share gain
sustain growth
test feel bit far away manag reiter guidanc
test access exceed vs approxim meet
target impli growth balanc vs
view forecast test growth last month
achiev requir ramp nip volum
prefer network drive consolid unit healthcar recent
disclos plan launch prefer laboratori network pln effect juli
one lab network believ structur like pln
may effect choke smaller lab certain specialti lab benefit
establish provid like see industri consolid
year price histori
diagnost test hereditari cancer
screen famili health plan
variou genet disord provid
predict prognost data
analyst certif import disclosur see disclosur
demand diagnost test unlik much healthcar
signific price elast use genom test
expand price sequenc declin best
posit test provid take advantag thesi base
grow economi scale commit drive
cog price lower singl price regardless breadth
genom data deliv breadth test menu
expect model result prefer access payer
relat market share gain upsid street revenu outlook
beyond
nipt test offer limit differenti account low single-
digit percentag sale
medicar reimburs ngs-base test
code unchang level outlin pama
gradual consolid hereditari cancer test market
continu industri remain highli fragment anoth
new collabor pharmaceut compani improv
test access patient suspect harbor rare diseas
addit partnership pharmaceut compani speed
adopt genom screen rare diseas popul
nipt offer meaning revenu contribut base
strength commerci channel
bolt-on acquisit acceler time-to-profit expand
propos medicar fee schedul cut reimburs ngs-
growth reproduct health non-oncolog indic
stall uptak earli adopt translat broad
genet test wide use cancer prenat care
pace adopt cardiovascular diseas immunolog
condit may slower anticip
pt base price-to-sal analysi assum multipl estim revenu million share
outstand discount back one year cost capit
risk reduct reimburs rate ngs-base genet test disrupt laboratori oper san francisco
facil result delay deliveri test result delay launch new product includ nipt neg impact revenu
growth failur fulli integr recent acquisit result reduc product lower return capit inabl
meet undisclos revenu coven relat debt facil
revenu revenu increas y-o-i estim
street consensu test volum quarter total y-o-i
estim report revenu per test total quarter
flat due season
gross margin gross margin compar year ago
forecast per test prior year
improv driven autom bill process economi scale
associ higher test volum
 administr expens increas estim
 sell expens increas estim
growth due higher test volum
 research spend increas versu forecast
ep net ep estim consensu
compani report oppenheim co inc estim
million except per opco estimate genet sell research profit interest incom profit loss per share continu incom loss loss per share averag common invita corp
reiter guidanc reiter guidanc
sampl revenu payment third-parti
payer account two-third revenu remaind institut
includ pharma partner patient pay
manag previous note roughli reduct reimburs hereditari
cancer test pama creat headwind
reproduct began see uptak nip account alreadi buy
carrier test manag expect signific contribut revenu
robust growth manag note nip test volum put upward pressur
cog near term
patient-initi test launch patient-initi test plan
invest commerci direct channel manag expect
patient-initi test avail product paid patient reimburs
insur depend specif patient
endometri cancer research merci medic center gynecolog
oncolog baltimor present data collabor studi endometri
cancer patient american colleg obstetrician gynecologist annual
meet patient cohort disease-caus variant
hereditari cancer gene higher previous report data
highlight import multigen panel test endometri cancer could
manag note strong volum intern market
account around diagnost test volum includ uptick carrier test
pharma partnership ad addit partnership program
network quarter bring network biopharma partner pharma
partnership report within institut segment account
revenu quarter
revenu reduc estiamt total revenu
base primarili weak result
gross margin increas estim gross margin
due mix shift toward cancer screen carri higher margin
 increas estim base
sell market increas sell expens estim
base manag guidanc selll expens increas faster rate
dtc spend patient-init test
 increas spend forecast due
expans test menu product develop
ep net revis ep forecast prior estim
prior consensu
compani report oppenheim co inc estim
genet sell research profit incom profit loss per share continu incom loss loss per share averag common analysisgross invita corp
